![](/img/cover-not-exists.png)
The quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) is safe and well tolerated as induction therapy for newly diagnosed, transplant eligible, myeloma patients
Pawlyn, C., Davies, F., Cairns, D., Collett, C., Jones, J., Kaiser, M., Chalmers, A., Striha, A., Milligan, D., Lindsay, J., Chapman, C., Allotey, D., Shafeek, S., Karunanithi, K., Cook, G., Russell,Volume:
15
Language:
english
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2015.07.188
Date:
September, 2015
File:
PDF, 138 KB
english, 2015